• Oculus Innovative Sciences (Petaluma, California) held an investigator meeting to review the ongoing Phase II clinical study underway, as well as a review of potential trial design and plans for the Phase III trials. Sixteen medical centers and clinics across the U.S. are participating in the current Phase II trial, which is a randomized and open-label study to evaluate the preliminary safety and efficacy of topical Microcyn technology for the treatment of mildly infected diabetic foot infections. The primary endpoint of the trial is clinical cure or improvement of infection. Oculus is a biopharmaceutical company that makes products based upon the Microcyn Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds.

• Pervasis Therapeutics (Cambridge, Massachusetts) reported the publication of new animal data for its Vascugel product under investigation to aid in healing, function, and remodeling of traumatized veins and arteries. The study suggested that Vascugel, a biologically-active matrix of endothelial cells that is placed directly on damaged blood vessels to stimulate natural repair and regeneration, was instrumental in increasing the diameter of injured vasculature, and reduced vascular narrowing, in tests utilizing a porcine model of arteriovenous (AV) grafts. Vascugel is an allogeneic cell therapy product for enhancing repair and preventing clinical failure of vascular surgery and intervention. Pervasis Therapeutics makes regenerative cell-based therapies and devices.